Abetimus: It is a synthetic toleragen
molecule con-sisting of four double-stranded oligo-deoxy-ribo-nuc-leotides attached to non-immunogenic polyethylene glycol.
The company also recently announced laboratory study results for a new Toleragen
candidate for antibody-mediated organ rejection in xenotransplantation.
La Jolla Pharmaceutical's other potential drug candidates, including its Toleragen
candidate for xenotransplantation, which have not progressed to clinical trials, involve comparable risks.
These studies show that we can suppress the production of the targeted antibodies and B cells using a number of Toleragen molecules," said Mathew Linnik Ph.
In the first study, titled "Tolerance Activity and Pharmacokinetics of Multivalent beta 2 GP1 Domain One Conjugates in an Immunized Animal Model," LJP scientists presented data on the efficacy and pharmacokinetics of several thrombosis Toleragen drug candidates in mouse and rat models of the disease.
is a treatment agent that is designed to bind to antibody receptors on the cell surface of targeted B cells and to send a signal that arrests the production of disease-causing antibodies.
The indications and optimal targets for autologous stem cell therapy in SLE, as well as the major indications for biologic therapies like B-cell depletion, inhibition of B-cell differentiation, costimulation blockade, and toleragens
LJP 394 uses Tolerance Technology to build Toleragens
, a class of therapeutics that are designed to arrest the B cells that produce disease-causing antibodies by binding to receptors on targeted B cells.